Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the potential of breath biomarkers for early detection and precision medicine through Breath Biopsy®. Breath Biopsy provides reliable solutions for the collection and analysis of volatile organic compounds (VOCs) produced through metabolic processes or as a result of interaction with external factors such as diet or medication. Changes to exhaled VOCs can be associated with a range of disease conditions and environmental exposures.
Eremid® Genomic Services is a high complexity CLIA-certified genomics contract research organization, with world-class scientific staff, and cutting-edge genomic instrumentation and automation to create a unique offering to meet the increasing demands for higher data quality, reliability, and accuracy in genomics research.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
Delivering innovative tools to basic and translational researchers. Our focus is directed towards advancing cellular analysis with flow cytometry cell analysers and sorters, fluorescently conjugated monoclonal antibodies as well as systems for single cell multiomics analysis. Bespoke antibody formulations, applications and assay design/development/optimization support as well as specific product training deliver holistic solutions to meet diverse customer needs.
Precision Antibody prides itself in developing application-specific antibodies with high specificity and sensitivity. In the field of biomarkers, the specificity and sensitivity of reagents are key performance characteristics for a successful assay development necessary for clinical application. With over 20 years of experience and expertise, Precision Antibody (PA) understands these challenges, offering a “one-stop shop” for many clients needing comprehensive application-specific antibody development services, from initial antigen design and immunization to antibody development, characterization, sequencing, and purification. Thanks to our ability to deliver antibodies that work in the intended assay in 60 days, PA has become a preferred vendor for many major pharmaceutical, biotech, and diagnostic companies, including many academic and government institutions, to fulfill their therapeutic and diagnostic needs.
Together with our partners, we create new, visionary products that can shape markets and benefit society. Our game-changing biosolutions solve some of the planet’s biggest challenges. Let’s rethink tomorrow together.
Company description: biocrates life sciences is a global leader in targeted metabolite products and services. Based in Innsbruck, Austria, with a subsidiary in the US, biocrates provides, standardized, quantitative, and FAIR compliant LC-MS/MS based technology covering more than 1000 metabolites. biocrates kit technology is designed for high throughput analyses that are scalable for longitudinal and large cohort studies with a focus on human and animal health, disease, nutrition, and the microbiome.
GeneCentric Therapeutics, Inc. is an RNA-based genomic solutions provider based in Durham, North Carolina. The company designed its technologies to parse the complexity of tumor and immune biology using its RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform to discover and develop signatures of responder populations to oncology therapeutics. GeneCentric commercializes its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout preclinical testing, clinical drug development and commercialization lifecycle phases.
Bioform solutions has developed a robust assay to monitor the cell health of probiotics, regardless of strains or the matrix. Flow cytometry is a single cell analysis tool. It can enumerate bacteria or yeast, alone or in a mix. It is the only way to enumerate heat killed cells (postbiotics) since they won’t grow. CFUs have been used in the industry for decades due to no extra equipment or knowledge needed, but the data has a 30-50% variability which leads to large questions about its accuracy. It also can only see cells that can grow in a particular media, so mixed strain probiotics can be very problematic. When the cells become stressed out due to processing and packaging, they can become viable but not culturable (VBNC), which means they won’t grow in a CFU assay. Flow cytometry gets around these issues by viewing all of the cells in a product, quickly and accurately with a CV <5%. Flow cytometry takes ~15 minutes whereas the CFU assay takes 3 days. This allows quick decisions to be made as a product is being formulated as well as determining the stability of the products.
HGF is one of Europe’s leading firms of Intellectual Property specialists. The firm is one of only a few to offer a fully integrated IP solution, bringing together patent attorneys, trade mark attorneys, design attorneys, IP solicitors and attorneys-at-law together across 22 offices in seven European countries, including Austria, France, Germany, Ireland, the Netherlands, Switzerland and the United Kingdom.
HGF creates and manages IP portfolios for the world’s leading companies and research institutes. We advise clients on the creation of strategic IP assets around the world and provide world-class expertise in oppositions, appeals, commercialisation, dispute resolution and litigation to defend and enforce IP rights.
Q2 Solutions is a leading global clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. Q2 Solutions uses global experience, innovation and scientific expertise to transform science and data into medical insights that turn hope into help. A joint venture of IQVIA and Quest Diagnostics, Q2 Solutions leverages each parent organization’s clinical trials laboratory capabilities and treats each sample as if a life depends on it.
We are a dynamic pre-clinical CRO offering the best-in-class in vitro simulations of the gastrointestinal tract to the food, functional food, feed and pharma industry. We offer a broad range of solutions for in vitro simulation of the gastrointestinal tract. Our technology platforms cover the physiology of the upper gastrointestinal tract, the physiology and the microbiology of the lower gastrointestinal tract and the microbiome-host interactions, and range from high-throughput screenings (Colon-on-a-plate®) to in-depth simulation of the long-term impact using the SHIME®.
By sharing our expertise and using our technology platforms, we assist your product development by building up essential know-how in the field of gastrointestinal transit, digestion, bioaccessibility, bioavailability, targeted delivery, drug dissolution, metabolism, microbial fermentation activity, ileal and colonic microbiome, gut barrier integrity, inflammation, immunomodulation and efficacy of probiotics, prebiotics, functional ingredients and pharmaceuticals, in relation to their fate and function in the body.
Recently we expanded our scope with a new business unit, MetaKey®, completely dedicated to metabolomics. In addition to classical UHPLC-HRMS-based untargeted and targeted metabolomics services, MetaKey® offers an innovative LA-REIMS platform for screening based on metabolic fingerprinting, which enables a high throughput at an affordable cost. Applications include analysis of any kind of matrix, but with a particular focus on microbial metabolism and interactions of microbiota with the human body.
A strong team, the desire to innovate and our customers’ satisfaction are at the core of our DNA. Our long-standing expertise and tailor-made solutions support your research from early phases to the final stages of product development. Our long-standing experience and expertise in studying the gastrointestinal processes at your service!
Zymo Research is a globally established biotechnology company and industry leader in the fields of microbiomics, epigenetics, and the emerging Next-Gen Sequencing space. From providing technologically advanced products to validated NGS services, everything is driven by the fundamental belief that "the beauty of science is to make things simple.
Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.
